Renovaro Inc. (NASDAQ:RENB) Sees Significant Decrease in Short Interest

Renovaro Inc. (NASDAQ:RENB) saw a large decline in short interest in the month of July. As of July 31st, there was short interest totaling 782,400 shares, adeclineof40.3% from the July 15th total of 1,310,000 shares. Currently,0.7% of the company’s shares are short sold. Based on an average daily volume of 3,560,000 shares, the days-to-cover ratio is presently 0.2 days. Based on an average daily volume of 3,560,000 shares, the days-to-cover ratio is presently 0.2 days. Currently,0.7% of the company’s shares are short sold.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Jane Street Group LLC acquired a new position in shares of Renovaro in the 2nd quarter valued at about $258,000. Qube Research & Technologies Ltd acquired a new position in shares of Renovaro in the 2nd quarter valued at about $66,000. Marshall Wace LLP acquired a new position in shares of Renovaro in the 2nd quarter valued at about $90,000. Nuveen LLC acquired a new position in shares of Renovaro in the 1st quarter valued at about $82,000. Finally, ProShare Advisors LLC acquired a new position in shares of Renovaro in the 4th quarter valued at about $27,000. 71.41% of the stock is owned by institutional investors and hedge funds.

Renovaro Price Performance

Shares of NASDAQ:RENB opened at $0.2341 on Wednesday. The company has a market capitalization of $40.29 million, a price-to-earnings ratio of -0.30 and a beta of 0.54. The business’s 50-day moving average is $0.30 and its 200-day moving average is $0.46. Renovaro has a 1 year low of $0.2201 and a 1 year high of $2.10.

Renovaro Company Profile

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.